Mark Olesnavage - Profile and Investment Details

Investor Profile

Mark Olesnavage is a Private Equity Firm, Venture Capital based in Grand Rapids, Michigan, United States with a diverse investment portfolio that includes companies such as Nymirum, Trapelo Health, Cirius Therapeutics, Metabolic Solutions Development, NeoChord, Sierra Oncology, Prevacept Infection Control, Bjond, Tolera Therapeutics, Delphinus Medical Technologies. Over time, Mark Olesnavage has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Mark Olesnavage is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Life Science, Information Services, Information Technology (IT), Biotech, Medical Device, Software, Healthcare, Biotechnology, Internet, Medical, Therapeutics, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Mark Olesnavage, as their portfolio suggests a familiarity and interest in this area.

Understanding Mark Olesnavage’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.